PI3Kγ INHIBITION POTENTIATES IMMUNE CHECKPOINT BLOCKADE

被引：0
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 01期
关键词：
D O I：
10.1158/2159-8290.CD-RW2016-216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [41] Inhibition of APOE potentiates immune checkpoint therapy for cancer
    Hui, Bingqing
    Lu, Chen
    Li, Haiyang
    Hao, Xiaopei
    Liu, Hanyuan
    Zhuo, Danping
    Wang, Qian
    Li, Zhouxiao
    Liu, Li
    Wang, Xuehao
    Gu, Yanhong
    Tang, Weiwei
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (14): : 5230 - 5240
  • [42] Dual PI3K blockade: PTCL's Achilles heel?
    Brammer, Jonathan E.
    BLOOD, 2018, 131 (08) : 839 - 840
  • [43] A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy
    Fan, Fushun
    Liu, Pei
    Bao, Rudi
    Chen, Jian
    Zhou, Minhua
    Mo, Zhenxian
    Ma, Yaru
    Liu, Haiqi
    Zhou, Yiping
    Cai, Xiong
    Qian, Changgeng
    Liu, Xinjian
    CANCER RESEARCH, 2021, 81 (24) : 6233 - 6245
  • [44] Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL
    Bojarczuk, Kamil
    Wienand, Kirsty
    Ryan, Jeremy A.
    Chen, Linfeng
    Villalobos-Ortiz, Mariana
    Mandato, Elisa
    Stachura, Joanna
    Lawton, Lee N.
    Letai, Anthony
    Chapuy, Bjoern
    Shipp, Margaret A.
    BLOOD, 2018, 132
  • [45] Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
    Bojarczuk, K.
    Wienand, K.
    Ryan, J. A.
    Chen, L.
    Villalobos-Ortiz, M.
    Mandato, E.
    Stachura, J.
    Letai, A.
    Lawton, L. N.
    Chapuy, B.
    Shipp, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 5 - 5
  • [46] Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
    Schwartz, Sarit
    Wongvipat, John
    Trigwell, Cath B.
    Hancox, Urs
    Carver, Brett S.
    Rodrik-Outmezguine, Vanessa
    Will, Marie
    Yellen, Paige
    de Stanchina, Elisa
    Baselga, Jose
    Scher, Howard I.
    Barry, Simon T.
    Sawyers, Charles L.
    Chandarlapaty, Sarat
    Rosen, Neal
    CANCER CELL, 2015, 27 (01) : 109 - 122
  • [47] PI3Kγ is a molecular switch that controls immune suppression
    Kaneda, Megan M.
    Messer, Karen S.
    Ralainirina, Natacha
    Li, Hongying
    Leem, Christopher J.
    Gorjestani, Sara
    Woo, Gyunghwi
    Nguyen, Abraham V.
    Figueiredo, Camila C.
    Foubert, Philippe
    Schmid, Michael C.
    Pink, Melissa
    Winkler, David G.
    Rausch, Matthew
    Palombella, Vito J.
    Kutok, Jeffery
    McGovern, Karen
    Frazer, Kelly A.
    Wu, Xuefeng
    Karin, Michael
    Sasik, Roman
    Cohen, Ezra E. W.
    Varner, Judith A.
    NATURE, 2016, 539 (7629) : 437 - 442
  • [48] PI3Kγ is a molecular switch that controls immune suppression
    Megan M. Kaneda
    Karen S. Messer
    Natacha Ralainirina
    Hongying Li
    Christopher J. Leem
    Sara Gorjestani
    Gyunghwi Woo
    Abraham V. Nguyen
    Camila C. Figueiredo
    Philippe Foubert
    Michael C. Schmid
    Melissa Pink
    David G. Winkler
    Matthew Rausch
    Vito J. Palombella
    Jeffery Kutok
    Karen McGovern
    Kelly A. Frazer
    Xuefeng Wu
    Michael Karin
    Roman Sasik
    Ezra E. W. Cohen
    Judith A. Varner
    Nature, 2016, 539 : 437 - 442
  • [49] Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
    Vachhani, Pankit
    Bose, Prithviraj
    Rahmani, Mohamed
    Grant, Steven
    PHYSIOLOGICAL GENOMICS, 2014, 46 (13) : 448 - 456
  • [50] Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
    Bojarczuk, Kamil
    Wienand, Kirsty
    Ryan, Jeremy A.
    Chen, Linfeng
    Villalobos-Ortiz, Mariana
    Mandato, Elisa
    Stachura, Joanna
    Letai, Anthony
    Lawton, Lee N.
    Chapuy, Bjoern
    Shipp, Margaret A.
    BLOOD, 2019, 133 (01) : 70 - 80
12345